# Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer

> **NCT02420977** · EARLY_PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 23 (actual)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** Pelvic DCFPyL PET-MRI fusion or PET/MRI

## Key facts

- **NCT ID:** NCT02420977
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2024-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02420977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02420977, "Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02420977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*